Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma

Abstract

Multiple myeloma is a clonal plasma cell malignancy within the bone marrow associated with bone loss, renal disease and immunodeficiency. Despite new insights into the pathogenesis of multiple myeloma and novel targeted therapies, the median survival remains 3–5 years. It is now well established that the intimate relation between the tumor cells and components of the microenvironment plays a key role in multiple myeloma pathogenesis. Specifically, tumor cells impact the bone marrow and thereby cause immune suppression and lytic bone lesions; conversely, components of the bone marrow provide signals that influence the behavior of multiple myeloma cells, including tumor cell growth, survival, migration and drug resistance. Important contributing effectors are tumor cell–stroma cell and cell–extracellular matrix contacts, the bone marrow vasculature, and a variety of cytokines and growth factors in the bone marrow milieu.

Keywords::

• angiogenesis
• bone marrow microenvironment
• combination/metronomic therapy
• multiple myeloma
• vascular endothelial growth factor

Acknowledgements

We thank all members of the Jerome Lipper Multiple Myeloma Center and Martin Sattler for many helpful discussions.

Notes

VEGF: Vascular endothelial growth factor.